Neue Erkenntnisse bei der Nitratwirkung, Nitratbioaktivierung und Toleranzentwicklung

Zusammenfassung

Nitrate stellen nach wie vor eine wichtige Säule in der Therapie des akuten Koronarsyndroms, der stabilen koronaren Herzerkrankung und der akuten und chronischen Herzinsuffizienz dar. Der prinzipielle Mechanismus der Vasodilatation beruht auf der Bildung des Stickstoffmonoxid (NO) oder einem chemisch verwandten Produkt, das die lösliche Guanylatzyklase aktiviert und über einen Abfall der intrazellulären Kalziumkonzentration den Gefäßtonus senkt und damit die Vasodilatation auslöst. Neuere Befunde zeigen, dass die Bioaktivierung hochreaktiver Nitrate wie des Nitroglyzerins (NTG) und des Pentaerthrityltetranitrat (PETN) durch ein mitochondrial lokalisiertes Enzym, der Aldehyddehydrogenase, kurz ALDH-2, bewerkstelligt wird. Das Bioaktivierungsenzym der Mono- und Dinitrate ist nach wie vor unbekannt. Trotz nachweislich guter antiischämischer Wirkung bei der Akut-Gabe ist die chronische Therapie mit organischen Nitraten durch 2 Nebenwirkungen limitiert: der Entwicklung einer Toleranz und einer endothelialen Dysfunktion. Sowohl die Toleranzentwicklung als auch die Nitrat-induzierte endotheliale Dysfunktion sind möglicherweise auf einen identischen Mechanismus, der vermehrten Bildung reaktiver Sauerstoffspezies zurückzuführen. In der Übersichtsarbeit werden neue Aspekte der Nitratbioaktivierung, die Ursachen der Toleranzentwicklung und der Entwicklung der endothelialen Dysfunktion sowie deren therapeutische Konsequenzen diskutiert. Ein weiterer Schwerpunkt sind neuere Ergebnisse bezüglich der NO-Donatoren Molsidomin, PETN, und der Kombinationstherapie bestehend aus dem Isosorbiddinitrat und Hydralazin in der Therapie der stabilen koronaren Herzerkrankung und der chronischen Herzinsuffizienz.

Summary

Organic nitrates still are one of the most important drug classes used in the treatment of an acute coronary syndrome and stable coronary artery disease as well as acute and chronic congestive heart failure. The mechanism of vasodilatation comprises the release of nitric oxide, which in turn activates soluble guanylate cyclase and lowers the intracellular calcium content leading to relaxation of vascular smooth muscle. Recent research has demonstrated that highly reactive nitrates, such as nitroglycerin (or glyceryl trinitrate) and pentaerthrityl tetranitrate (PETN) are bioactivated by aldehyde dehydrogenase 2 (ALDH-2), an enzyme located in mitochondria. The enzyme, which bioactivates mono- and dinitrates is not yet identified. Despite being effective in the acute treatment of patients, its long-term efficacy is limited by the development of tolerance to nitrates and of endothelial dysfunction. Both of these side effects of nitrate therapy are due to increased production of reactive oxygen species. This review focuses on new aspects of the process of bioactivation of organic nitrates, the conception of oxidative stress of endothelial dysfunction and of the development of tolerance and their therapeutic consequences. Also discussed are more recent findings on nitric oxide donors such as molsidomine, PETN and the combination treatment of isosorbide dinitrate and hydralazine of patients with coronary artery disease and chronic heart failure.

Nitrate - Nitroglyzerin - Stickstoffmonoxid - Pentaerythrityltetranitrat - Medikamententoleranz - Koronare Herzkrankheit

nitrates - nitroglycerin - nitric oxide - pentaerythretyl tetranitrate - drug tolerance - coronary heart disease

Literatur

• 1 Abrams J. Glyceryl trinitrate (nitroglycerin) and the organic nitrates. Choosing the method of administration.  Drugs. 1987;  34 391-403
• 2 Anand I S, Tam S W, Rector T S. et al . Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial.  J Am Coll Cardiol. 2007;  49 32-39
• 3 Azevedo E R, Schofield A M, Kelly S, Parker J D. Nitroglycerin withdrawal increases endothelium-dependent vasomotor response to acetylcholine.  J Am Coll Cardiol. 2001;  37 505-509
• 4 Caramori P R, Adelman A G, Azevedo E R. et al . Therapy with nitroglycerin increases coronary vasoconstriction in response to acetylcholine.  J Am Coll Cardiol. 1998;  32 1969-1974
• 5 Chen Z, Zhang J, Stamler J S. Identification of the enzymatic mechanism of nitroglycerin bioactivation.  Proc Natl Acad Sci U S A. 2002;  99 8306-8311
• 6 Cohn J N, Archibald D G, Ziesche S. et al . Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study.  The New England journal of medicine. 1986;  314 1547-1552
• 7 Cohn J N, Johnson G, Ziesche S. et al . A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.  The New England journal of medicine. 1991;  325 303-310
• 8 Daiber A, Oelze M, Coldewey M. et al . Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure.  Biochem Biophys Res Commun. 2005;  338 1865-1874
• 9 Daiber A, Oelze M, Coldewey M. et al . Oxidative stress and mitochondrial aldehyde dehydrogenase activity: a comparison of pentaerythritol tetranitrate with other organic nitrates.  Mol Pharmacol. 2004;  66 1372-1382
• 10 Esplugues J V, Rocha M, Nunez C. et al . Complex I dysfunction and tolerance to nitroglycerin: an approach based on mitochondrial-targeted antioxidants.  Circ Res. 2006;  99 1067-1075
• 11 Franciosa J A, Blank R C, Cohn J N. Nitrate effects on cardiac output and left ventricular outflow resistance in chronic congestive heart failure.  Am J Med. 1978;  64 207-213
• 12 Franciosa J A, Cohn J N. Hemodynamic responsiveness to short- and long-acting vasodilators in left ventricular failure.  Am J Med. 1978;  65 126-133
• 13 Gogia H, Mehra A, Parikh S. et al . Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure.  J Am Coll Cardiol. 1995;  26 1575-1580
• 14 Gori T, Burstein J M, Ahmed S. et al . Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: a human in vivo study.  Circulation. 2001;  104 1119-1123
• 15 Gori T, Mak S S, Kelly S, Parker J D. Evidence supporting abnormalities in nitric oxide synthase function induced by nitroglycerin in humans.  J Am Coll Cardiol. 2001;  38 1096-1101
• 16 Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease.  Circulation. 2001;  104 2673-2678
• 17 Hink U, Oelze M, Kolb P. et al . Role for peroxynitrite in the inhibition of prostacyclin synthase in nitrate tolerance.  J Am Coll Cardiol. 2003;  42 1826-1834
• 18 Jurt U, Gori T, Ravandi A. et al . Differential effects of pentaerythritol tetranitrate and nitroglycerin on the development of tolerance and evidence of lipid peroxidation: a human in vivo study.  J Am Coll Cardiol. 2001;  38 854-859
• 19 Kuzkaya N, Weissmann N, Harrison D G, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbic acid, and thiols: implications for uncoupling endothelial nitric-oxide synthase.  J Biol Chem. 2003;  278 22546-22554
• 20 Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance.  Circ Res. 2005;  97 618-628
• 21 Munzel T, Feil R, Mulsch A. et al . Physiology and pathophysiology of vascular signaling controlled by guanosine 3’,5’-cyclic monophosphate-dependent protein kinase [corrected].  Circulation. 2003;  108 2172-2183
• 22 Munzel T, Giaid A, Kurz S, Stewart D J, Harrison D G. Evidence for a role of endothelin 1 and protein kinase C in nitroglycerin tolerance.  Proc Natl Acad Sci U S A. 1995;  92 5244-5248
• 23 Munzel T, Heitzer T, Kurz S. et al . Dissociation of coronary vascular tolerance and neurohormonal adjustments during long-term nitroglycerin therapy in patients with stable coronary artery disease.  J Am Coll Cardiol. 1996;  27 297-303
• 24 Munzel T, Sayegh H, Freeman B A, Tarpey M M, Harrison D G. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance.  J Clin Invest. 1995;  95 187-194
• 25 Oberle S, Abate A, Grosser N. et al . Endothelial protection by pentaerithrityl trinitrate: bilirubin and carbon monoxide as possible mediators.  Exp Biol Med (Maywood). 2003;  228 529-534
• 26 Pfeifer A, Klatt P, Massberg S. et al . Defective smooth muscle regulation in cGMP kinase I-deficient mice.  Embo J. 1998;  17 3045-3051
• 27 Silber S. Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.  Eur J Clin Pharmacol. 1990;  38 Suppl 1 S35-51
• 28 Taylor A L, Ziesche S, Yancy C. et al . Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.  The New England journal of medicine. 2004;  351 2049-2057
• 29 Thomas G R, DiFabio J M, Gori T, Parker J D. Once daily therapy with isosorbide-5-mononitrate causes endothelial dysfunction in humans: evidence of a free-radical-mediated mechanism.  J Am Coll Cardiol. 2007;  49 1289-1295
• 30 Thum T, Fraccarollo D, Thum S, Schultheiss M, Daiber A, Wenzel P, Munzel T, Ertl G, Bauersachs J. Differential effects of organic nitrates on endothelial progenitor cells are determined by oxidative stress.  Arterioscler Thromb Vasc Biol.. 2007;  27 748-754
• 31 Wenzel P, Hink U, Oelze M. et al . Number of nitrate groups determines reactivity and potency of organic nitrates: a proof of concept study in ALDH-2-/- mice.  Br J Pharmacol. 2007;  150 526-533
• 32 Wenzel P, Oelze M, Coldewey M. et al . Heme oxygenase-1: a novel key player in the development of tolerance in response to organic nitrates.  Arterioscler Thromb Vasc Biol. 2007;  27 1729-1735